{"id":"peg-asparaginase-at-six-weeks-interval","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypersensitivity reactions"},{"rate":null,"effect":"Pancreatitis"},{"rate":null,"effect":"Thrombosis"},{"rate":null,"effect":"Hepatotoxicity"},{"rate":null,"effect":"Coagulopathy"},{"rate":null,"effect":"Nausea and vomiting"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Asparaginase is an enzyme that catalyzes the hydrolysis of asparagine to aspartic acid and ammonia. Acute lymphoblastic leukemia (ALL) cells are often asparagine synthetase-deficient and depend on exogenous asparagine for survival. By depleting circulating asparagine, the drug induces apoptosis in leukemic blasts while sparing most normal cells that can synthesize asparagine endogenously. PEGylation extends the drug's half-life, allowing for less frequent dosing intervals.","oneSentence":"PEG Asparaginase depletes the amino acid asparagine in the bloodstream, starving leukemic cells that cannot synthesize their own asparagine.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:26:07.087Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute lymphoblastic leukemia (ALL), as part of combination chemotherapy"}]},"trialDetails":[{"nctId":"NCT00819351","phase":"PHASE3","title":"ALL2008 Protocol for Childhood Acute Lymphoblastic Leukemia Intermittent Versus Continuous PEG Asparaginase","status":"COMPLETED","sponsor":"Rigshospitalet, Denmark","startDate":"2009-01-01","conditions":"Acute Lymphoblastic Leukemia","enrollment":650}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Oncaspar (PEG-Asparaginase)"],"phase":"phase_3","status":"active","brandName":"PEG Asparaginase at six weeks interval","genericName":"PEG Asparaginase at six weeks interval","companyName":"Rigshospitalet, Denmark","companyId":"rigshospitalet-denmark","modality":"Small molecule","firstApprovalDate":"","aiSummary":"PEG Asparaginase depletes the amino acid asparagine in the bloodstream, starving leukemic cells that cannot synthesize their own asparagine. Used for Acute lymphoblastic leukemia (ALL), as part of combination chemotherapy.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}